Vikram Narayan

Department of Urology
Assistant Professor

(404) 778-4898
@VikramNarayan

Overview

Dr. Vikram Narayan specializes in the surgical treatment of urologic cancers and has a research focus in the management of bladder and urothelial cancers.

Dr. Narayan received his MD degree from the University of Florida College of Medicine in 2013. His general surgery internship and urology residency were done at the University of Minnesota, after which he completed a fellowship in urologic oncology at the University of Texas MD Anderson Cancer in 2020. During his fellowship, Dr. Narayan completed a year of basic science research investigating novel therapeutics for urothelial cancers including intravesical gene therapy, immune-based treatment options, and the role of the urinary microbiome in bladder cancer treatment.

Dr. Narayan's current research interests concentrate on understanding the mechanisms that underlie bladder cancer treatment responses in order to improve patients' therapeutic options. He has led projects studying quality outcomes for patients being treated for urothelial cancer. Dr. Narayan additionally has an interest in methodologic research, and has published several peer-reviewed articles about the performance of clinical urologic research and the transparent reporting of randomized trials and systematic reviews.

Academic Appointment

Assistant Professor of Urology, Department of Urology, Emory University School of Medicine
Director of Urological Oncology, Grady Memorial Hospital

Education

Degrees

MD (Graduated with Honors in Research) from University of Florida College of Medicine, Gainesville, FL

Research

Publications

Incidence of New Mental Health Diagnosis in Testicular Cancer Survivors.
Urology
04/16/2025 Authors: Marthi S; Palmateer G; Helman T; Patil D; Nicaise E; Goodstein T; Ogan K; Narayan V; Master V; Joshi SS
A luminal non-coding RNA-based genomic classifier confirms favourable outcomes in patients with clinically organ-confined bladder cancer treated with radical cystectomy.
BJU Int Volume: 135 Page(s): 648 - 656
04/01/2025 Authors: de Jong JJ; Proudfoot JA; Daneshmand S; Svatek RS; Narayan V; Gibb EA; Davicioni E; Joshi S; Dahmen A; Li R
Minimal Residual Disease Detection with Urine-derived DNA Is Prognostic for Recurrence-free Survival in Bacillus Calmette-Gurin-unresponsive Non-muscle-invasive Bladder Cancer Treated with Nadofaragene Firadenovec.
Eur Urol Oncol Volume: 8 Page(s): 425 - 434
04/01/2025 Authors: Narayan VM; Tholomier C; Mokkapati S; Martini A; Caruso VM; Goudarzi M; Mazzarella BC; Phillips KG; Bicocca VT; Levin TG
Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial.
Nat Cancer Volume: 6 Page(s): 432 - 444
03/01/2025 Authors: Bilen MA; Vo BT; Liu Y; Greenwald R; Davarpanah AH; McGuire D; Shiradkar R; Li L; Midya A; Nazha B
Molecular Subtyping for Predicting Pathological Upstaging and Survival Outcomes in Clinically Organ-confined Bladder Cancer Patients Undergoing Radical Cystectomy.
Eur Urol Open Sci Volume: 73 Page(s): 24 - 30
03/01/2025 Authors: de Jong JJ; Proudfoot JA; Daneshmand S; Svatek RS; Narayan V; Davicioni E; Joshi S; Dahmen A; Li R; Inman BA
Characteristics, Treatment, and Outcomes of Primary Urethral Cancer: A Multicenter Review Over Two Decades.
Clin Genitourin Cancer Volume: 23 Page(s): 102276
02/01/2025 Authors: Hopkins BD; Qian DC; Xu KM; McCook-Veal A; Switchenko J; Hartsell LM; Cimmino CB; Joshi SS; Narayan V; Master VA
Predicting Response to Intravesical Bacillus Calmette-Gurin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12-Center Cohort.
J Urol Volume: 213 Page(s): 192 - 204
02/01/2025 Authors: Lotan Y; Krishna V; Abuzeid WM; Launer B; Chang SS; Krishna V; Shingi S; Gordetsky JB; Gerald T; Woldu S
Differentiation fate of a stem-like CD4 T cell controls immunity to cancer.
Nature Volume: 636 Page(s): 224 - 232
12/01/2024 Authors: Cardenas MA; Prokhnevska N; Sobierajska E; Gregorova P; Medina CB; Valanparambil RM; Greenwald R; DelBalzo L; Bilen MA; Joshi SS
Paraneoplastic Syndrome Prevalence and Survival in Racially-Diverse Cohort With Renal Cell Carcinoma.
Clin Genitourin Cancer Volume: 22 Page(s): 102207
12/01/2024 Authors: Nicaise EH; Schmeusser BN; Palmateer G; Vashi K; Parikh K; Patil D; Shapiro DD; Abel EJ; Joshi S; Narayan V
Author Correction: Differentiation fate of a stem-like CD4 T cell controls immunity to cancer.
Nature Volume: 635 Page(s): E9
11/01/2024 Authors: Cardenas MA; Prokhnevska N; Sobierajska E; Gregorova P; Medina CB; Valanparambil RM; Greenwald R; DelBalzo L; Bilen MA; Joshi SS
PD-L1 and nectin-4 expression and genomic characterization of bladder cancer with divergent differentiation.
Cancer Volume: 130 Page(s): 3658 - 3670
11/01/2024 Authors: Martini DJ; Case KB; Gratz D; Pellegrini K; Beagle E; Schneider T; Dababneh M; Nazha B; Brown JT; Joshi SS
Paraneoplastic Resolution Holds Prognostic Utility in Patients with Metastatic Renal Cell Carcinoma.
Cancers (Basel) Volume: 16
10/01/2024 Authors: Palmateer G; Nicaise EH; Goodstein T; Schmeusser BN; Patil D; Imtiaz N; Shapiro DD; Abel EJ; Joshi S; Narayan V
Tailoring language for genitourinary function in patients with newly diagnosed prostate cancer to facilitate discussions in diverse populations and overcome health literacy barriers.
Cancer Volume: 130 Suppl 20 Page(s): 3602 - 3611
10/15/2024 Authors: Kilbridge KL; Patil D; Filson CP; Shelton JW; Thomson SW; Rosenbaum CH; Rothmann EC; Martin-Doyle W; Trinh Q-D; Narayan VM
Reply: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gurin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
J Urol Volume: 212 Page(s): 625
10/01/2024 Authors: Dinney CPN; Narayan VM
Immunotherapy for advanced or metastatic urothelial carcinoma: an abridged Cochrane review.
BJU Int Volume: 134 Page(s): 541 - 550
10/01/2024 Authors: Maisch P; Hwang EC; Kim K; Narayan VM; Bakker C; Kunath F; Dahm P
Neoadjuvant cabozantinib restores CD8+ T cells in patients with locally advanced non-metastatic clear cell renal cell carcinoma: a phase 2 trial.
Res Sq
08/08/2024 Authors: Bilen MA; Vo BT; Liu Y; Greenwald R; Davarpanah AH; McGuire D; Shiradkar R; Li L; Nazha B; Brown JT
Standardization of the evaluation and surveillance of patients with BCG unresponsive high grade non-muscle invasive bladder cancer clinical trials.
Urol Oncol Volume: 42 Page(s): 223 - 228
08/01/2024 Authors: Lotan Y; Agarwal P; Black P; Dickstein R; Kamat AM; Lee B; Narayan VM; Porten S; Psutka SP; Smith AK
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gurin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
J Urol Volume: 212 Page(s): 74 - 86
07/01/2024 Authors: Narayan VM; Boorjian SA; Alemozaffar M; Konety BR; Shore ND; Gomella LG; Kamat AM; Bivalacqua TJ; Montgomery JS; Lerner SP
Linear Muscle Segmentation for Metastatic Renal Cell Carcinoma: Changes in Clinic-Friendly Estimation Predict Survival Following Cytoreductive Nephrectomy.
Clin Genitourin Cancer Volume: 22 Page(s): 102056
06/01/2024 Authors: Nicaise EH; Schmeusser BN; Ali A; Midenberg E; Palacios AR; Hartsoe B; Kearns E; Ambadi S; Patil DH; Joshi SS
2018 Leibovich prognostic model for renal cell carcinoma: Performance in a large population with special consideration of Black race.
Cancer Volume: 130 Page(s): 453 - 466
02/01/2024 Authors: Schmeusser BN; Patil DH; Nicaise EH; Armas-Phan M; Nabavizadeh R; Narayan VM; Joshi SS; Ogan K; Osunkoya AO; Bilen MA
Mechanism of action of nadofaragene firadenovec-vncg.
Front Oncol Volume: 14 Page(s): 1359725
01/01/2024 Authors: Narayan VM; Meeks JJ; Jakobsen JS; Shore ND; Sant GR; Konety BR
Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors.
Oncologist Volume: 28 Page(s): 1072 - 1078
12/11/2023 Authors: Sanda GE; Shabto JM; Goyal S; Liu Y; Martini DJ; Nazha B; Brown JT; Yantorni LB; Anne Russler G; Caulfield S
Creatinine to Cystatin-C Ratio in Renal Cell Carcinoma: A Clinically Pragmatic Prognostic Factor and Sarcopenia Biomarker.
Oncologist Volume: 28 Page(s): e1219 - e1229
12/11/2023 Authors: Schmeusser BN; Biermann H; Nicaise EH; Ali AA; Patil DH; Midenberg E; Helman T; Armas-Phan M; Nabavizadeh R; Joshi SS
Immunotherapy for advanced or metastatic urothelial carcinoma.
Cochrane Database Syst Rev Volume: 10 Page(s): CD013774
10/09/2023 Authors: Maisch P; Hwang EC; Kim K; Narayan VM; Bakker C; Kunath F; Dahm P
Evaluation of a Natural Language Processing Model to Identify and Characterize Patients in the United States With High-Risk Non-Muscle-Invasive Bladder Cancer.
JCO Clin Cancer Inform Volume: 7 Page(s): e2300096
09/01/2023 Authors: Narayan VM; Siolas D; Meadows ES; Turzhitsky V; Sillah A; Imai K; McMurry AJ; Li H
Low Skeletal Muscle as a Risk Factor for Worse Survival in Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus.
Clin Genitourin Cancer Volume: 21 Page(s): 475 - 482.e4
08/01/2023 Authors: Schmeusser BN; Midenberg E; Palacios AR; Ali AA; Patil DH; Higgins M; Nabavizadeh R; Croll B; Williams M; Sheehy J
Prolonged Opioid Use Following Bladder Tumor Resection for Opioid-nave Patients.
Urol Pract Volume: 10 Page(s): 345 - 351
07/01/2023 Authors: Croll B; Patil D; Mason M; Narayan VM; Master V; Filson CP; Joshi SS
PATHOLOGIC DOWNSTAGING RATE AND PREDICTIVE BIOMARKER EXPLORATION IN PATIENTS WITH BIOPSY-PROVEN CLINICALLY NODE POSITIVE BLADDER CANCER UNDERGOING CHEMOTHERAPY FOLLOWED BY RADICAL CYSTECTOMY
Volume: 209 Page(s): E775 - E775
04/01/2023 Authors: Lim A; Sood A; Narayan V; Seif M; Matulay J; Bree K; Campbell M; Kamat A; Dinney C; Navai N
Challenges and opportunities in the management of non-urothelial bladder cancers.
Cancer Treat Res Commun Volume: 34 Page(s): 100663
01/01/2023 Authors: Brown JT; Narayan VM; Joshi SS; Harik L; Jani AB; Bilen MA
Prostatic arterial embolisation for men with benign prostatic hyperplasia: a Cochrane review.
BJU Int Volume: 131 Page(s): 32 - 45
01/01/2023 Authors: Jung JH; McCutcheon KA; Borofsky M; Young S; Golzarian J; Kim MH; Narayan V; Dahm P
Blue vs white light for transurethral resection of non-muscle-invasive bladder cancer: an abridged Cochrane Review.
BJU Int Volume: 130 Page(s): 730 - 740
12/01/2022 Authors: Maisch P; Koziarz A; Vajgrt J; Narayan V; Kim MH; Dahm P
Photodynamic Diagnosis-Assisted Transurethral Resection - Lights Out?
NEJM Evid Volume: 1 Page(s): EVIDe2200194
10/01/2022 Authors: Dahm P; Narayan VM
Extramammary Paget's disease: Updates in the workup and management.
Asian J Urol Volume: 9 Page(s): 451 - 459
10/01/2022 Authors: Nabavizadeh R; Vashi KB; Nabavizadeh B; Narayan VM; Master VA
Sarcopenia and systemic inflammation are associated with decreased survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Cancer Volume: 128 Page(s): 2073 - 2084
06/01/2022 Authors: Khan AI; Psutka SP; Patil DH; Hong G; Williams MA; Bilen MA; Sekhar A; Kissick HT; Narayan VM; Joshi SS
RENAL FUNCTIONAL CHANGES AFTER CYSTECTOMY: WHO IMPROVES AND WHO DOES NOT?
Volume: 207 Page(s): E971 - E971
05/01/2022 Authors: Croll B; Patil D; Vashi K; Alemozaffar M; Master V; Filson C; Ogan K; Narayan V; Joshi S
Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Cochrane Database Syst Rev Volume: 3 Page(s): CD012867
03/29/2022 Authors: Jung JH; McCutcheon KA; Borofsky M; Young S; Golzarian J; Kim MH; Narayan VM; Dahm P
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial.
Eur Urol Volume: 81 Page(s): 223 - 228
03/01/2022 Authors: Mitra AP; Narayan VM; Mokkapati S; Miest T; Boorjian SA; Alemozaffar M; Konety BR; Shore ND; Gomella LG; Kamat AM
Extramammary Paget's Disease of genitourinary origin.
Curr Opin Urol Volume: 32 Page(s): 211 - 215
03/01/2022 Authors: Narayan VM; Master VA
The naked truth: a comprehensive clarification and classification of current 'myths' in naked mole-rat biology.
Biol Rev Camb Philos Soc Volume: 97 Page(s): 115 - 140
02/01/2022 Authors: Buffenstein R; Amoroso V; Andziak B; Avdieiev S; Azpurua J; Barker AJ; Bennett NC; Brieo-Enrquez MA; Bronner GN; Coen C
Clinic friendly estimation of muscle composition: Preoperative linear segmentation shows overall survival correlated with muscle mass in patients with nonmetastatic renal cell carcinoma.
Front Oncol Volume: 12 Page(s): 1068357
01/01/2022 Authors: Schmeusser BN; Midenberg E; Palacios AR; Vettikattu N; Patil DH; Medline A; Higgins M; Armas-Phan M; Nabavizadeh R; Joshi SS
Altering the microbiome for immunotherapy-resistant urological tumors-An intriguing but still early concept.
Cancer Volume: 128 Page(s): 20 - 21
01/01/2022 Authors: Narayan VM
Blue versus white light for transurethral resection of non-muscle invasive bladder cancer.
Cochrane Database Syst Rev Volume: 12 Page(s): CD013776
12/01/2021 Authors: Maisch P; Koziarz A; Vajgrt J; Narayan V; Kim MH; Dahm P
Longitudinal impact of bladder cancer diagnosis on common psychiatric disorders.
Volume: 10 Page(s): 8412 - 8420
12/01/2021 Authors: Cooke IJ; Patil D; Bobrek K; Narayan V; Master V; Rapaport M; Filson CP; Joshi SS
Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review.
Investig Clin Urol Volume: 62 Page(s): 623 - 630
11/01/2021 Authors: Han MA; Maisch P; Jung JH; Hwang JE; Narayan V; Cleves A; Hwang EC; Dahm P
Gene Expression Profiling of Muscle-Invasive Bladder Cancer With Secondary Variant Histology.
Am J Clin Pathol Volume: 156 Page(s): 895 - 905
10/13/2021 Authors: de Jong JJ; Narayan VM; Cronican AA; Gupta S; van Leenders GJLH; Boormans JL; Gibb EA; Konety BR
EDITORIAL COMMENT.
Urology Volume: 156 Page(s): 197 - 198
10/01/2021 Authors: Narayan VM
ANTI-ADENOVIRAL ANTIBODY LEVELS PREDICT NADOFARAGENE FIRADENOVEC RESPONSE IN BCG-UNRESPONSIVE NMIBC: RESULTS FROM A PHASE 3 TRIAL
Volume: 206 Page(s): E119 - E120
09/01/2021 Authors: Mitra AP; Narayan VM; Boorjian SA; Alemozaffar M; Konety BR; Shore ND; Gomella LG; Kamat AM; Bivalacqua TJ; Montgomery JS
Oncologic Equipoise Between Robotic and Open Radical Cystectomy.
J Endourol Volume: 35 Page(s): 1168 - 1176
08/01/2021 Authors: Kukreja JB; Li R; Narayan VM; Lim A; Seif M; Wang X; Kamat A; Dinney C; Navai N
A Helpful Tool in the Renal Surgery Armamentarium: Dorsal Lumbotomy nephrectomy for Tumor in Patients with End-Stage Renal Disease.
Urology Volume: 153 Page(s): 327 - 332
07/01/2021 Authors: Cooke I; Sadruddin S; Patil D; Tripathi S; Nabavizadeh R; Joshi S; Narayan V; Ogan K; Master VA
Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma.
Cancer Volume: 127 Page(s): 1974 - 1983
06/15/2021 Authors: Higgins MI; Martini DJ; Patil DH; Nabavizadeh R; Steele S; Williams M; Joshi SS; Narayan VM; Sekhar A; Psutka SP
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Cochrane Database Syst Rev Volume: 6 Page(s): CD009294
06/14/2021 Authors: Han MA; Maisch P; Jung JH; Hwang JE; Narayan V; Cleves A; Hwang EC; Dahm P
Significant anti-adenovirus antibody response positively correlates with efficacy in patients treated with nadofaragene firadenovec for high-grade BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
Volume: 79 Page(s): S1028 - S1029
06/01/2021 Authors: Narayan V; Boorjian S; Alemozaffer M; Konety BR; Gomella L; Kamat AM; Lerner SP; Svatek RS; Karsh L; Canter D
Subgroup analyses of the phase 3 study of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
Volume: 79 Page(s): S1026 - S1027
06/01/2021 Authors: Narayan V; Boorjian S; Alemozaffer M; Konety BR; Gomella L; Kamat AM; Lerner SP; Svatek RS; Karsh L; Canter D
Reply by Authors.
J Urol Volume: 205 Page(s): 1620 - 1621
06/01/2021 Authors: Matulay JT; Li R; Hensley PJ; Brooks NA; Narayan VM; Grossman HB; Navai N; Dinney CPN; Kamat AM
Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Gurin: Implications for Clinical Trial Design.
J Urol Volume: 205 Page(s): 1612 - 1621
06/01/2021 Authors: Matulay JT; Li R; Hensley PJ; Brooks NA; Narayan VM; Grossman HB; Navai N; Dinney CPN; Kamat AM
Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted Biopsy COMMENT
JOURNAL OF UROLOGY Volume: 205 Page(s): 1351 - 1351
05/01/2021 Authors: Narayan VM
Editorial Comment.
J Urol Volume: 205 Page(s): 1351
05/01/2021 Authors: Narayan VM
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
Lancet Oncol Volume: 22 Page(s): 107 - 117
01/01/2021 Authors: Boorjian SA; Alemozaffar M; Konety BR; Shore ND; Gomella LG; Kamat AM; Bivalacqua TJ; Montgomery JS; Lerner SP; Busby JE
Insights into the Molecular Basis of Genome Stability and Pristine Proteostasis in Naked Mole-Rats.
Adv Exp Med Biol Volume: 1319 Page(s): 287 - 314
01/01/2021 Authors: Narayan V; McMahon M; O'Brien JJ; McAllister F; Buffenstein R
Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Cochrane Database Syst Rev Volume: 12 Page(s): CD012867
12/19/2020 Authors: Jung JH; McCutcheon KA; Borofsky M; Young S; Golzarian J; Reddy B; Shin TY; Kim MH; Narayan V; Dahm P
The role of the urologist, BCG vaccine administration, and SARS-CoV-2: An overview.
BJUI Compass Volume: 1 Page(s): 87 - 92
07/01/2020 Authors: Brooks NA; Narayan V; Hegarty PK; Zafirakis H; Han X-Y; Kamat AM
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Lancet Volume: 395 Page(s): 1907 - 1918
06/20/2020 Authors: Kuderer NM; Choueiri TK; Shah DP; Shyr Y; Rubinstein SM; Rivera DR; Shete S; Hsu C-Y; Desai A; de Lima Lopes G
TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer.
Mol Cancer Res Volume: 18 Page(s): 811 - 821
06/01/2020 Authors: Mokkapati S; Porten SP; Narayan VM; Lim AH; Jayaratna IS; Roth B; Cheng T; Navai N; Wszolek M; Melquist J
Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes.
Urol Oncol Volume: 38 Page(s): 247 - 254
04/01/2020 Authors: Narayan VM; Seif MA; Lim AH; Li R; Matulay JT; Kukreja JB; Qiao W; Hwang H; Shah JB; Pisters L
NOVEL COMBINATION THERAPY USING LENTIVIRAL INTERFERON AND IMMUNE CHECKPOINT BLOCKADE FOR TREATMENT OF BLADDER CANCER IN A MURINE MODEL
Volume: 203 Page(s): E830 - E830
04/01/2020 Authors: Kokorovic A; Mokkapati S; Duplisea J; Plote D; Lim A; Narayan VM; Metcalfe MJ; Nieminen T; Heikura T; Seppo Y-H
Quality of Intervention Reporting in Randomized Clinical Trials Published in Urology Journals.
Eur Urol Volume: 77 Page(s): 296 - 298
03/01/2020 Authors: Johnson BS; Fladie I; Jellison S; McMurray M; Narayan V; Vassar M
A critical appraisal of biomarkers in prostate cancer.
World J Urol Volume: 38 Page(s): 547 - 554
03/01/2020 Authors: Narayan VM
Intravesical Gene Therapy.
Urol Clin North Am Volume: 47 Page(s): 93 - 101
02/01/2020 Authors: Narayan VM; Dinney CPN
Bacillus Calmette-Gurin Salvage Therapy: Definitions and Context.
Urol Clin North Am Volume: 47 Page(s): 1 - 4
02/01/2020 Authors: Konety BR; Narayan VM; Dinney CPN
The Role of Surgery in Initially Metastatic Urothelial Carcinoma: Informing a Definitive Trial.
Eur Urol Oncol Volume: 3 Page(s): 102 - 103
02/01/2020 Authors: Lim AH; Narayan VM; Navai N
The future of clinical trials in urological oncology.
Nat Rev Urol Volume: 16 Page(s): 722 - 733
12/01/2019 Authors: Narayan VM; Dahm P
Genomic Analysis and Treatment Response of a Bladder Urothelial Carcinoma With Sarcomatoid Variant Histology.
Clin Genitourin Cancer Volume: 17 Page(s): e888 - e892
10/01/2019 Authors: Narayan VM; Gupta S; Davicioni E; Murugan P; Gibb EA; Konety B
The impact of squamous histology on survival in patients with muscle-invasive bladder cancer.
Urol Oncol Volume: 37 Page(s): 353.e17 - 353.e24
06/01/2019 Authors: Matulay JT; Woldu SL; Lim A; Narayan VM; Li G; Kamat AM; Anderson CB
Re: Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-sparing Trimodality Therapy for Muscle-invasive Bladder Cancer.
Eur Urol Volume: 75 Page(s): 1034 - 1035
06/01/2019 Authors: Narayan VM; Lim AH; Dinney CPN
Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Cochrane Database Syst Rev Volume: 5 Page(s): CD012832
05/25/2019 Authors: Jung JH; Reddy B; McCutcheon KA; Borofsky M; Narayan V; Kim MH; Dahm P
THE IMPACT OF NEOADJUVANT CHEMOTHERAPY FOR SQUAMOUS HISTOLOGY IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER
Volume: 201 Page(s): E925 - E925
04/01/2019 Authors: Matulay J; Woldu S; Narayan V; Lim A; McIntosh A; Kamat A; Anderson C
CONTEMPORARY OUTCOMES OF NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS TREATED WITH INDUCTION BCG
Volume: 201 Page(s): E618 - E618
04/01/2019 Authors: Matulay J; Li R; Navai N; Nagaraju S; Narayan V; Lim A; Grossman HB; Czerniak B; Guo C; Dinney C
A comprehensive assessment of postoperative complications in female patients undergoing robot versus open radical cystectomy.
Volume: 37
03/01/2019 Authors: Narayan VM; Seif M; Lim A; Li R; Qiao W; Hwang H; Dinney CPN; Navai N
Lentiviral interferon: A novel method for gene therapy in bladder cancer.
Volume: 37
03/01/2019 Authors: Mokkapati S; Duplisea JJ; Plote D; Narayan VM; Lim A; Metcalfe MJ; Dunner K; Czerniak B; Nieminen T; Heikura T
Clinical and Genomic Considerations for Variant Histology in Bladder Cancer.
Curr Oncol Rep Volume: 21 Page(s): 23
02/26/2019 Authors: Matulay JT; Narayan VM; Kamat AM
Bladder changes after catheterizable channel creation in adults with cerebral palsy who are in chronic urinary retention.
Neurourol Urodyn Volume: 38 Page(s): 165 - 170
01/01/2019 Authors: Narayan VM; Pariser JJ; Gor RA; Katorski J; Elliott SP
The History of Urology at the Minneapolis Veterans Affairs Health Care System.
Urology Volume: 123 Page(s): 7 - 11
01/01/2019 Authors: Lane G; Uloko M; Narayan V; J J Ercole C
Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
Cochrane Database Syst Rev Volume: 7 Page(s): CD012838
07/23/2018 Authors: Narayan V; Kahlmeyer A; Dahm P; Skoetz N; Risk MC; Bongiorno C; Patel N; Hwang EC; Jung JH; Gartlehner G
The fragility of statistically significant findings from randomised controlled trials in the urological literature.
BJU Int Volume: 122 Page(s): 160 - 166
07/01/2018 Authors: Narayan VM; Gandhi S; Chrouser K; Evaniew N; Dahm P
Racial disparities and considerations for active surveillance of prostate cancer.
Transl Androl Urol Volume: 7 Page(s): 214 - 220
04/01/2018 Authors: Jiang S; Narayan V; Warlick C
A systematic assessment of Cochrane reviews and systematic reviews published in high-impact medical journals related to cancer.
BMJ Open Volume: 8 Page(s): e020869
03/25/2018 Authors: Goldkuhle M; Narayan VM; Weigl A; Dahm P; Skoetz N
The Prevalence and Impact of Urinary Marker Testing in Patients with Bladder Cancer.
J Urol Volume: 199 Page(s): 74 - 80
01/01/2018 Authors: Narayan VM; Adejoro O; Schwartz I; Ziegelmann M; Elliott S; Konety BR
The Effects of Population-based Prostate-specific Antigen Screening Beginning at Age 40.
Urology Volume: 110 Page(s): 127 - 133
12/01/2017 Authors: Weight CJ; Narayan VM; Smith D; Kim SP; Karnes RJ
Re: Richard J. Sylvester, Steven E. Canfield, Thomas B.L. Lam, et al. Conflict of Evidence: Resolving Discrepancies When Findings from Randomized Controlled Trials and Meta-analyses Disagree. Eur Urol 2017;71:811-9.
Eur Urol Volume: 72 Page(s): e91 - e92
10/01/2017 Authors: Dahm P; Narayan V; Jung JH
Re: Efficacy and Safety of Prostatic Arterial Embolization: Systematic Review with Meta-Analysis and Meta-Regression: S. R. Shim, K. J. Kanhai, Y. M. Ko and J. H. Kim J Urol 2017;197:465-479.
J Urol Volume: 198 Page(s): 215 - 216
07/01/2017 Authors: Narayan V; Jung JH; Dahm P
Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice.
Int J Urol Volume: 24 Page(s): 352 - 360
05/01/2017 Authors: Narayan VM; Konety BR; Warlick C
The landscape of systematic reviews in urology (1998 to 2015): an assessment of methodological quality.
BJU Int Volume: 119 Page(s): 638 - 649
04/01/2017 Authors: Han JL; Gandhi S; Bockoven CG; Narayan VM; Dahm P
Evaluating Region of Interest Measurement Strategies to Characterize Upper Urinary Tract Stones on Computerized Tomography.
J Urol Volume: 197 Page(s): 715 - 722
03/01/2017 Authors: Narayan VM; Bozorgmehri S; Ellen JH; Canales MT; Canales BK; Bird VG
Early Stage Cancer in Older Adults: Prostate-Avoiding Overtreatment and Undertreatment.
Cancer J Volume: 23 Page(s): 238 - 241
01/01/2017 Authors: Narayan V; Jiang S; Warlick CA
Improved Reporting of Randomized Controlled Trials in the Urologic Literature.
Eur Urol Volume: 70 Page(s): 1044 - 1049
12/01/2016 Authors: Narayan VM; Cone EB; Smith D; Scales CD; Dahm P
Defining the publication source of high-quality evidence in urology: an analysis of EvidenceUpdates.
BJU Int Volume: 117 Page(s): 861 - 866
06/01/2016 Authors: Narayan VM; Chrouser K; Haynes RB; Parrish R; Dahm P

Directory section navigation

Profile